J Loader, FC Taylor, E Lampa… - Journal of the American …, 2022 - Am Heart Assoc
Background Renin‐angiotensin aldosterone system (RAAS) inhibitor—COVID‐19 studies, observational in design, appear to use biased methods that can distort the interaction …
GM Vahey, E McDonald, K Marshall, SW Martin… - PloS one, 2021 - journals.plos.org
Background Most current evidence on risk factors for hospitalization because of coronavirus disease 2019 (COVID-19) comes from studies using data abstracted primarily from …
C Chu, S Zeng, AA Hasan, CF Hocher… - British Journal of …, 2021 - Wiley Online Library
Aims Angiotensin‐converting enzyme‐2 (ACE2) is the receptor for SARS‐CoV‐2. Animal studies suggest that renin–angiotensin–aldosterone system (RAAS) blockers might increase …
The coronavirus disease 2019 (COVID-19) pandemic has placed immense pressure on health care services, necessitating reorganization and reprioritization of resources and …
J Loader, E Lampa, S Gustafsson, T Cars… - Journal of the …, 2021 - Am Heart Assoc
Background Considering the widespread risk of collider bias and confounding by indication in previous research, the associations between renin‐angiotensin aldosterone system …
C Dayaramani, J De Leon, AB Reiss - Medicina, 2021 - mdpi.com
SARS-CoV-2, a single-stranded RNA coronavirus, causes an illness known as coronavirus disease 2019 (COVID-19). The highly transmissible virus gains entry into human cells …
The renin–angiotensin system is a complex, coordinated hormonal cascade that plays a pivotal role in controlling individual cell behaviour and multiple organ functions. ACE2 acts …
Background There has been uncertainty about the safety or benefit of angiotensin- converting enzyme (ACE) inhibitors during the COVID-19 pandemic. We used Mendelian …
K Mackey, D Kansagara, K Vela - Annals of Internal Medicine, 2021 - acpjournals.org
We searched MEDLINE (Ovid) weekly from 27 October to 23 November 2020 using the same search strategy as described in the original review (1). We did not limit the search by …